Last reviewed · How we verify

NCT04962256

ERAS in Posterior Approach of Cervical Spine Operation

Completed Last updated 12 October 2022
What this trial tests

trial testing Enhanced recovery after surgery in Cervical Myelopathy in 204 participants. Completed in 31 March 2022.

Timeline
20 March 2019
Primary endpoint
31 March 2022
31 March 2022

Quick facts

Lead sponsorPeking University Third Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment204
Start date20 March 2019
Primary completion31 March 2022
Estimated completion31 March 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 70, any sex, with Cervical Myelopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Enhanced recovery after surgery (ERAS) strategy has been used in the patient management of different diseases. This study aims to evaluate the effectiveness of ERAS in the perioperative period of posterior approach of cervical spine operation among patients with CSM.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Enhanced recovery after surgery

Trials testing the same drug.

Other recruiting trials for Cervical Myelopathy

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04962256.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing